drugset / Trial / NCT01511978
Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Hypothesis: 3,4-Diaminopyridine base (3,4-DAP) improves Lambert-Eaton Myasthenic Syndrome (LEMS)-related weakness.
Timeline
- Start
- 2012-01
- Primary completion
- 2014-02
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amifampridine | Small molecule | 30 mg | — |
| Comparator | Amifampridine | Small molecule | 100 mg | — |